• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by BrainsWay Ltd.

    4/20/26 4:06:32 PM ET
    $BWAY
    Medical/Dental Instruments
    Health Care
    Get the next $BWAY alert in real time by email
    S-8 1 fs8_041626.htm FORM S-8

    As filed with the Securities and Exchange Commission on April 20, 2026

     

    Registration No. 333-_______

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

     

    BRAINSWAY LTD.

    (Exact name of registrant as specified in its charter)

     

     

     

    State of Israel   Not Applicable
    (State or other jurisdiction of   (I.R.S. Employer
    incorporation or organization)   Identification No.)

     

    16 Hartum Street

    RAD Tower, 14th Floor

    Har HaHotzvim

    Jerusalem, 9777516, Israel

    (Address of Principal Executive Offices, including Zip Code)

     

     

     

    Brainsway Ltd. 2019 Share Incentive Plan

    (Full title of the plan)

     

     

     

    BrainsWay USA, Inc.

    95 Washington Street

    Suite 104-323

    Canton, MA 02021, USA

    (Name and address of agent for service)

     

     

     

    (844) 386-7001

    (Telephone number, including area code, of agent for service)

     

    Copies to:

     

    Rick A. Werner, Esq.

    Jayun Koo, Esq.

    Haynes and Boone, LLP

    30 Rockefeller Plaza

    26th Floor

    New York, New York 10112

    Tel: +1 212 659-7300

    Sarit Molcho, Adv.

    Odeya Brick-Zarsky, Adv.

    S. Friedman, Abramson & Co.

    Azrieli Town

    146 Menachem Begin Road

    Tel Aviv 6492103, Israel

    Tel: +972 (3) 693-1931

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

      Large Accelerated Filer ☐   Accelerated Filer ☒
      Non-Accelerated Filer ☐   Smaller Reporting Company ☐
          Emerging Growth Company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

     

    EXPLANATORY NOTE

     

    This Registration Statement is filed by BrainsWay Ltd. (the “Registrant”), for the purpose of registering 3,023,921 ordinary shares, par value NIS 0.04 per share (“Ordinary Shares”), either issuable or reserved and available for issuance under the Registrant’s 2019 Share Incentive Plan (the “2019 Plan”).

     

    PART I

     

    INFORMATION REQUIRED IN THE PROSPECTUS

     

    The information specified in Item 1 and Item 2 of Part I of Form S-8 is omitted from this Registration Statement on Form S-8 (the “Registration Statement”) in accordance with the provisions of Rule 428 under the Securities Act of 1933, as amended (the “Securities Act”). The documents containing the information specified in Part I of Form S-8 will be delivered to the participants in the equity benefit plans covered by this Registration Statement as specified by Rule 428(b)(1) under the Securities Act.

     

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION statement

     

    Item 3. Incorporation of Documents by Reference.

     

    The following documents filed by the Registrant with the Securities and Exchange Commission (the “Commission”), pursuant to the Securities Exchange Act of 1934 (the “Exchange Act”) (Commission File No. 001-35165), are incorporated herein by reference:

     

    (a)       The Registrant’s Annual Report on Form 20-F for the fiscal year ended December 31, 2025 filed with the Commission on April 20, 2026 (the “2025 Annual Report”);

     

    (b)       All other reports filed by the Registrant with the Commission pursuant to Sections 13(a) or 15(d) of the Exchange Act since the end of the fiscal year covered by the Registrant’s Annual Report referred to in (1) above; and

     

    (c)       The description of the Registrant’s Ordinary Shares and American Depositary Shares (“ADSs”) contained in the registration statements under the Exchange Act on Form 8-A as filed with the Commission on April 11, 2019, as amended by Exhibit 2.3 to the 2025 Annual Report, and including any subsequent amendment or report filed for the purpose of updating such description.

     

    All documents filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement that indicates that all securities offered have been sold or that deregisters all securities then remaining unsold shall be deemed to be incorporated by reference in this Registration Statement and to be part hereof from the date of filing of such documents; provided, however, that documents or information deemed to have been furnished and not filed in accordance with the rules of the Commission shall not be deemed incorporated by reference into this Registration Statement. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document which also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

     

     

     

    Item 4. Description of Securities.

     

    Not Applicable.

     

    Item 5. Interests of Named Experts and Counsel.

     

    Not Applicable.

     

    Item 6. Indemnification of Directors and Officers.

     

    Exculpation

     

    Under the Israeli Companies Law, 1999 (the “Israeli Companies Law”), a company may not exculpate (or exempt) an office holder from liability for a breach of the fiduciary duty. An Israeli company may exculpate an office holder in advance from liability to the company, in whole or in part, for damages caused to the company as a result of a breach of the office holder’s duty of care but only if a provision authorizing such exculpation is included in its articles of association. A company may not exculpate in advance a director from liability arising due to the breach of his or her duty of care in connection with dividend or distribution to shareholders.

     

    Indemnification

     

    Under the Israeli Companies Law, the Israeli Securities Law, 5728-1968 (the “Israeli Securities Law”) and the Israeli Economic Competition Law, 5748-1988 (the “Israeli Competition Law”) a company may indemnify an office holder in respect of the following liabilities, payments, and expenses incurred for acts performed by him or her as an office holder, either in advance of an event or following an event, provided its articles of association include a provision authorizing such indemnification:

     

    ●        a monetary liability incurred by or imposed on the office holder in favor of another person pursuant to a court judgment, including pursuant to a settlement confirmed as judgment or arbitrator’s decision approved by a competent court. However, if an undertaking to indemnify an office holder with respect to such liability is provided in advance, then such an undertaking must be limited to events which, in the opinion of the board of directors, can be foreseen based on the company’s activities when the undertaking to indemnify is given, and to an amount or according to criteria determined by the board of directors as reasonable under the circumstances, and such undertaking shall detail the abovementioned foreseen events and amount or criteria; (ii) concluded without the filing of an indictment against the office holder but with the imposition of a monetary obligation on the office holder in lieu of criminal proceedings for an offense that does not require proof of criminal intent; or (iii) in connection with a monetary sanction;

     

    ●        reasonable litigation expenses, including reasonable attorneys’ fees, which were incurred by the office holder as a result of an investigation or proceeding filed against the office holder by an authority authorized to conduct such investigation or proceeding, provided that such investigation or proceeding was either (i) concluded without the filing of an indictment against such office holder and without the imposition on him of any monetary obligation in lieu of a criminal proceeding;

     

     

     

     

    ●        a monetary liability imposed on the office holder in favor of a payment for a breach offended at an Administrative Procedure (as defined below) as set forth in Section 52(54)(a)(1)(a) to the Israeli Securities Law;

     

    ●        expenses expended by the office holder with respect to an Administrative Procedure under the Israeli Securities Law, including reasonable litigation expenses and reasonable attorneys’ fees;

     

    ●        reasonable litigation expenses, including attorneys’ fees, incurred by the office holder or which were imposed on the office holder by a court (i) in a proceeding instituted against him or her by the company, on its behalf, or by a third party, (ii) in connection with criminal indictment of which the office holder was acquitted, or (iii) in a criminal indictment which the office holder was convicted of an offense that does not require proof of criminal intent; and

     

    ●        any other obligation or expense in respect of which it is permitted or will be permitted under applicable law to indemnify an office holder, including, without limitation, matters referenced in Section 56H(b)(1) of the Israeli Securities Law.

     

    An “Administrative Procedure” is defined as a procedure pursuant to chapters H3 (Monetary Sanction by the Israeli Securities Authority), H4 (Administrative Enforcement Procedures of the Administrative Enforcement Committee) or I1 (Arrangement to prevent Procedures or Interruption of procedures subject to conditions) to the Israeli Securities Law.

     

    Insurance

     

    Under the Israeli Companies Law, the Israeli Securities Law and the Israeli Competition Law, a company may insure an office holder against the following liabilities incurred for acts performed by him or her as an office holder if and to the extent provided in the company’s articles of association:

     

    ●         a breach of the fiduciary duty to the company, provided that the office holder acted in good faith and had a reasonable basis to believe that the act would not harm the company;

     

    ●         a breach of duty of care to the company or to a third party, to the extent such a breach arises out of the negligent conduct of the office holder;

     

    ●         a monetary liability imposed on the office holder in favor of a third party;

     

    ●         a monetary liability imposed on the office holder in favor of an injured party at an Administrative Procedure pursuant to Section 52(54)(a) (1)(a) of the Israeli Securities Law; and

     

    ●         expenses incurred by an office holder in connection with an Administrative Procedure, including reasonable litigation expenses and reasonable attorneys’ fees.

     

     

     

     

    Limitations on, and Approval Process of, Exculpation, Indemnification and Insurance

     

    Under the Israeli Companies Law, a company may not indemnify, exculpate or insure an office holder against any of the following:

     

    ●         a breach of the fiduciary duty, except for indemnification and insurance for a breach of the fiduciary duty to the company to the extent that the office holder acted in good faith and had a reasonable basis to believe that the act would not prejudice the company;

     

    ●         a breach of duty of care committed intentionally or recklessly, excluding a breach solely arising out of the negligent conduct of the office holder;

     

    ●         an act or omission committed with intent to derive illegal personal benefit; or

     

    ●         a fine, civil fine, financial sanction or forfeit levied against the office holder.

     

    Under the Israeli Companies Law, exculpation, indemnification, and insurance of office holders must be approved by the compensation committee and the board of directors, and, with respect to directors or controlling shareholders, their relatives and third parties in which controlling shareholders have a personal interest, also by the shareholders.

     

    Our articles of association and compensation policy permit us to exculpate, indemnify, and insure our office holders to the fullest extent permitted or to be permitted by law. Our office holders are currently covered by a directors’ and officers’ liability insurance policy. As of the date of this report, no claims for directors’ and officers’ liability insurance have been filed under this policy, and we are not aware of any pending or threatened litigation or proceeding involving any of our office holders, including our directors, in which indemnification is sought.

     

    We have entered into agreements with each of our current office holders exculpating them from a breach of their duty of care to us to the fullest extent permitted by law, subject to limited exceptions, and undertaking to indemnify them to the fullest extent permitted by law, subject to limited exceptions, to the extent that these liabilities are not covered by insurance. This indemnification is limited, with respect to any monetary liability imposed in favor of a third party, to events determined as foreseeable by the board of directors based on our activities. The maximum aggregate amount of indemnification that we may pay to our office holders based on such indemnification agreement with respect to any monetary liability imposed in favor of a third party is the greater of (1) 25% of our shareholders’ equity less the minority rights pursuant to our audited or reviewed consolidated financial statements at the time the indemnification is actually paid, and (2) $20 million. Such indemnification is in addition to any insurance amounts. However, in the opinion of the SEC, indemnification of office holders for liabilities arising under the Securities Act is against public policy and therefore unenforceable. SEC Position. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling us pursuant to the foregoing provisions, we have been informed that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.

     

    Item 7. Exemption from Registration Claimed.

     

    Not Applicable.

     

     

     

     

    Item 8. Exhibits.

     

    Exhibit Number Name
    4.1 Articles of Association of the Registrant, as amended (incorporated by reference to Exhibit A of Exhibit 99.1 to the Form 6-K filed by the Registrant with the Commission on October 1, 2024).
    4.2 Amended and Restated BrainsWay 2019 Share Incentive Plan (incorporated by reference to Exhibit 4.1 to the Company’s Annual Report on Form 20-F filed by the Company with the SEC on April 19, 2021).
    5.1* Opinion of S. Friedman, Abramson & Co.
    23.1* Consent of Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global, an independent registered public accounting firm.
    23.2* Consent of S. Friedman, Abramson & Co. (included in Exhibit 5.1 to this Registration Statement).
    24.1* Power of Attorney (included in signature page).
    107* Filing Fee Table.

     

    * Filed herewith.

     

    Item 9.Undertakings.

     

    (a) The undersigned Registrant hereby undertakes:

     

    (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

     

    (i)       To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933, as amended (the “Securities Act”);

     

    (ii)       To reflect in the prospectus any facts or events arising after the effective date of this Registration Statement (or the most recent post-effective amendment hereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in this Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20 percent change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective Registration Statement; and

     

    (iii)       To include any material information with respect to the plan of distribution not previously disclosed in this Registration Statement or any material change to such information in this Registration Statement;

     

    provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) above do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in periodic reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in this Registration Statement.

     

    (2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (3) To remove from registration, by means of a post-effective amendment, any of the securities being registered which remain unsold at the termination of the offering.

     

     

     

     

    (b) The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or 15(d) of the Exchange Act that is incorporated by reference in this Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Israel on the 20th day of April, 2026. 

     

      BRAINSWAY LTD.
      (Registrant)
       
      By: /s/ Hadar Levy      
      Hadar Levy
      Chief Executive Officer

     

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Hadar Levy and Ido Marom, and either of such persons acting alone, as his or her true and lawful agent, proxy and attorney-in-fact, with full power of substitution and resubstitution, for him and in his name, place and stead, in any and all capacities, to (i) act on, sign and file with the Securities and Exchange Commission any and all amendments (including post-effective amendments) to this Registration Statement together with all schedules and exhibits thereto, (ii) act on, sign and file with the Securities and Exchange Commission any registration statement relating to this offering that is to be effective upon filing pursuant to Rule 462(b) under the Securities Act of 1933, as amended, (iii) act on, sign and file with the Securities and Exchange Commission any exhibits to such registration statement or pre-effective or post-effective amendments, (iv) act on, sign and file such certificates, instruments, agreements and other documents as may be necessary or appropriate in connection therewith, (v) act on and file any supplement to any reoffer prospectus included in this registration statement or any such amendment and (vi) take any and all actions which may be necessary or appropriate in connection therewith, granting unto such agents, proxies and attorneys-in-fact, and each of them, full power and authority to do and perform each and every act and thing necessary or appropriate to be done (including with respect to any reoffer prospectus included in this registration statement), as fully for all intents and purposes as he or she might or could do in person, hereby approving, ratifying and confirming all that such agents, proxies and attorneys-in-fact, any of them or any of his, her or their substitute or substitutes may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act, this registration statement has been signed below by the following persons on the dates and in the capacities indicated.

     

     

    Signature   Title   Date
             
    /s/ Hadar Levy   Chief Executive Officer   April 20, 2026
    Hadar Levy        
             
    /s/ Ido Marom   Chief Financial Officer   April 20, 2026
    Ido Marom        
             
    /s/ Ami Boehm   Chairman of the Board   April 20, 2026
    Ami Boehm        
             
    /s/ Dr. David Zacut   Vice Chairman of the Board   April 20, 2026
    Dr. David Zacut        

     

     

     

     

     

             
    /s/ Karen Sarid   Director   April 20, 2026
    Karen Sarid        
             
    /s/ Eti Mitrany   Director   April 20, 2026
    Eti Mitrany        
             
    /s/ Prof. Abraham Zangen   Director   April 20, 2026
    Prof. Abraham Zangen        
             
    /s/ Avner Lushi   Director   April 20, 2026
    Avner Lushi        
             
    /s/ Jonathan Shulkin   Director   April 20, 2026
    Jonathan Shulkin        
             

     

    Authorized Representative in the U.S.:

     

     

      BrainsWay USA, Inc.
      Authorized U.S. Representative
       
       
      By:     /s/ Ido Marom                                      
      Name: Ido Marom
      Title: Chief Financial Officer

     

     

     

     

    Get the next $BWAY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BWAY

    DatePrice TargetRatingAnalyst
    11/16/2023Outperform → Mkt Perform
    Raymond James
    3/3/2022$15.00Buy
    Loop Capital
    11/29/2021$14.00 → $15.00Buy
    HC Wainwright & Co.
    8/12/2021$17.00 → $14.00Buy
    HC Wainwright & Co.
    7/19/2021$17.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $BWAY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Zangen Abraham

    3 - Brainsway Ltd. (0001505065) (Issuer)

    3/18/26 4:05:51 PM ET
    $BWAY
    Medical/Dental Instruments
    Health Care

    SEC Form 3 filed by new insider Mitrany Rayten Michal Ety

    3 - Brainsway Ltd. (0001505065) (Issuer)

    3/18/26 4:05:45 PM ET
    $BWAY
    Medical/Dental Instruments
    Health Care

    SEC Form 3 filed by new insider Zacut David

    3 - Brainsway Ltd. (0001505065) (Issuer)

    3/18/26 4:05:17 PM ET
    $BWAY
    Medical/Dental Instruments
    Health Care

    $BWAY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BrainsWay Highlights Growing U.S. Payer Support for Nurse Practitioner-Administered Transcranial Magnetic Stimulation (TMS) Therapy

    BURLINGTON, Mass. and JERUSALEM, April 15, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today highlighted the growing trend across the U.S. payer landscape of coverage policies that allow appropriately trained nurse practitioners to administer Transcranial Magnetic Stimulation (TMS) therapy. A growing number of commercial insurers, Medicare Administrative Contractors (MACs), and government payers now permit psychiatric mental health nurse practitioners (PMHNPs) to administer TMS therapy, including Deep TMS™, when practicing in accordance with app

    4/15/26 7:30:00 AM ET
    $BWAY
    Medical/Dental Instruments
    Health Care

    BrainsWay to Participate in the 25th Annual Needham Virtual Healthcare Conference

    BURLINGTON, Mass. and JERUSALEM, April 13, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that management will present at the 25th Annual Needham Virtual Healthcare Conference at 8:45 AM ET on Wednesday, April 15, 2026. Please contact your Needham & Co. representative to request a meeting at the conference. About BrainsWayBrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulati

    4/13/26 8:00:00 AM ET
    $BWAY
    Medical/Dental Instruments
    Health Care

    BrainsWay Completes Additional $6 Million Milestone-Based Investment in Neurolief Ltd. Following FDA Approval of Proliv™Rx System for MDD

    BURLINGTON, Mass. and JERUSALEM, March 26, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced the completion of an additional $6 million milestone-based convertible loan to Neurolief Ltd. ("Neurolief"). This second tranche investment was triggered by the recent U.S. Food and Drug Administration (FDA) Premarket Approval (PMA) for Neurolief's Proliv™Rx system, a milestone defined under the terms of BrainsWay's August 2025 strategic investment transaction with Neurolief. "Our strategic investments in Neurolief are part of our long-term mi

    3/26/26 7:30:00 AM ET
    $BWAY
    Medical/Dental Instruments
    Health Care

    $BWAY
    SEC Filings

    View All

    SEC Form S-8 filed by BrainsWay Ltd.

    S-8 - Brainsway Ltd. (0001505065) (Filer)

    4/20/26 4:06:32 PM ET
    $BWAY
    Medical/Dental Instruments
    Health Care

    SEC Form S-8 POS filed by BrainsWay Ltd.

    S-8 POS - Brainsway Ltd. (0001505065) (Filer)

    4/20/26 4:05:04 PM ET
    $BWAY
    Medical/Dental Instruments
    Health Care

    SEC Form 20-F filed by BrainsWay Ltd.

    20-F - Brainsway Ltd. (0001505065) (Filer)

    4/20/26 4:01:32 PM ET
    $BWAY
    Medical/Dental Instruments
    Health Care

    $BWAY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Brainsway downgraded by Raymond James

    Raymond James downgraded Brainsway from Outperform to Mkt Perform

    11/16/23 7:31:55 AM ET
    $BWAY
    Medical/Dental Instruments
    Health Care

    Loop Capital initiated coverage on BrainsWay with a new price target

    Loop Capital initiated coverage of BrainsWay with a rating of Buy and set a new price target of $15.00

    3/3/22 4:42:28 AM ET
    $BWAY
    Medical/Dental Instruments
    Health Care

    HC Wainwright & Co. reiterated coverage on BrainsWay with a new price target

    HC Wainwright & Co. reiterated coverage of BrainsWay with a rating of Buy and set a new price target of $15.00 from $14.00 previously

    11/29/21 6:24:14 AM ET
    $BWAY
    Medical/Dental Instruments
    Health Care

    $BWAY
    Financials

    Live finance-specific insights

    View All

    BrainsWay Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

    Q4 Revenue Grew 27% Year-Over-Year to Record $14.5 Million Q4 Operating Income of $1.9 Million; Adjusted EBITDA Increased by 53% to $2.3 Million, Reflecting Significant Operating Leverage  Full Year 2025 Revenue Increased by Approximately 27% YoY to $52.2 Million, and Net Income Increased by Approximately 161% YoY to $7.6 Million Remaining Performance Obligations Increased 43% to Approximately $70 Million Issuing 2026 Guidance: Expecting Revenue of $66 - $68 million (27% - 30% Growth), Operating Income of 13% - 14%, and Adjusted EBITDA of $12 - $14 Million (86% - 100% Growth) Conference Call to be Held Today at 8:30 AM ET BURLINGTON, Mass. and JERUSALEM, March 11, 2026 (GLOBE NEWSWIR

    3/11/26 7:30:00 AM ET
    $BWAY
    Medical/Dental Instruments
    Health Care

    BrainsWay to Report Fourth Quarter and Full Year 2025 Financial Results on March 11, 2026

    BURLINGTON, Mass. and JERUSALEM, Feb. 25, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation technologies, today announced that it will report its fourth quarter and full year 2025 financial results, as well as operational highlights, before the open of the U.S. financial markets on Wednesday, March 11, 2026. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations. Conference Call Dial-In & Webcast Information Date:Wednesday, March 11, 2026Time:8:30 AM Eastern TimeUnited States:1-877-300-8521Internationa

    2/25/26 8:00:00 AM ET
    $BWAY
    Medical/Dental Instruments
    Health Care

    BrainsWay Reports Third Quarter 2025 Financial Results and Operational Highlights

    Revenue increased 29% to $13.5 million in Q3 2025 as compared with Q3 2024 Operating income totaled $1.3 million and Adjusted EBITDA rose approximately 80% to $2.0 million in Q3 2025, as compared with Q3 2024 Remaining performance obligations increased to $65 million FDA cleared an accelerated protocol for Deep TMS treatment of patients with major depressive disorder (MDD) Raised midpoint of full-year 2025 Revenue and EBITDA guidance Conference call to be held today at 8:30 AM ET BURLINGTON, Mass. and JERUSALEM, Israel, Nov. 11, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatm

    11/11/25 7:30:00 AM ET
    $BWAY
    Medical/Dental Instruments
    Health Care

    $BWAY
    Leadership Updates

    Live Leadership Updates

    View All

    MindWalk Appoints R. Scott Areglado as Chief Financial Officer to Strengthen Financial Leadership and Support Growth Strategy

    MindWalk Holdings Corp.™ ("MindWalk," "Company," "we" or "us") (NASDAQ:HYFT), bio-native AI company today announces the appointment of industry veteran R. Scott Areglado as Chief Financial Officer (CFO), effective October 20, 2025. "Scott's extensive experience leading financial strategy for high-growth, publicly traded healthcare and technology companies makes him an ideal addition to our executive team," said Dr. Jennifer Bath, MindWalk CEO. "His proven ability to strengthen financial systems, execute disciplined growth initiatives, and communicate effectively with the investment community will be instrumental as we scale our Bio-Native AI platform globally." Mr. Areglado brings more

    10/21/25 8:28:00 AM ET
    $BWAY
    $HYFT
    $ICAD
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations

    BrainsWay Appoints Richard A. Bermudes, M.D. as Chief Medical Officer

    BURLINGTON, Mass. and JERUSALEM, Aug. 29, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced the appointment of Richard A. Bermudes, M.D. as Chief Medical Officer (CMO), effective September 1, 2024. Dr. Aron Tendler, M.D., who has served as CMO since 2015, will continue to serve as a collaborator on important strategic research projects. "We are excited to have Richard join our team to lead and shape BrainsWay's clinical strategy and product roadmap. His extensive experience with TMS and brain stimulation therapies as a practicing phys

    8/29/24 7:30:00 AM ET
    $BWAY
    Medical/Dental Instruments
    Health Care

    Murchinson Takes Action to Replace Board of Directors of Nano Dimension at Upcoming Annual General Meeting

    Highlights Entrenchment Tactics Taken by the Board Before and Following March Special Meeting Where Shareholders Overwhelmingly Supported Murchinson's Case for Change – Including the Removal of CEO and Chairman Yoav Stern From the Board Puts Forward Proposals to Improve Company's Failed Corporate Governance by Seeking to Remove All Current Directors and Appoint Five New, Experienced and Independent Nominees Murchinson Ltd. (collectively with its affiliates and funds it advises and/or sub-advises, "Murchinson" or "we"), a significant shareholder with approximately 5.9% of the outstanding shares of Nano Dimension Ltd., a company incorporated in Israel (NASDAQ:NNDM) ("Nano Dimension" or th

    8/3/23 3:00:00 PM ET
    $BWAY
    $INSG
    $MCK
    Medical/Dental Instruments
    Health Care
    Telecommunications Equipment
    Telecommunications

    $BWAY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by BrainsWay Ltd.

    SC 13G/A - Brainsway Ltd. (0001505065) (Subject)

    11/14/24 1:33:58 PM ET
    $BWAY
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by BrainsWay Ltd.

    SC 13G/A - Brainsway Ltd. (0001505065) (Subject)

    11/14/24 1:32:48 PM ET
    $BWAY
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13D filed by BrainsWay Ltd.

    SC 13D - Brainsway Ltd. (0001505065) (Subject)

    11/13/24 6:09:51 PM ET
    $BWAY
    Medical/Dental Instruments
    Health Care